Craft

GlycoMimetics

Stock Price

$1.8

2024-05-03

Market Capitalization

$117.9 M

2024-05-03

Revenue

$10 K

FY, 2023

GlycoMimetics Summary

Company Summary

Overview
GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.
Type
Public
Status
Active
Founded
2003
HQ
Rockville, MD, US | view all locations
Website
http://www.glycomimetics.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Brian Hahn

    Brian Hahn, Chief Financial Officer and Senior Vice President

  • Rachel K. King

    Rachel K. King, Director

    • Harout Semerjian

      Harout Semerjian, President and Chief Executive Officer

    • Helen Thackray

      Helen Thackray, Chief Medical Officer & Senior Vice President, Clinical Development

    LocationsView all

    1 location detected

    • Rockville, MD HQ

      United States

      9708 Medical Center Dr

    GlycoMimetics Financials

    Summary Financials

    Net income (Q1, 2024)
    ($10.7M)
    Cash (FY, 2023)
    $41.8M
    EBIT (Q1, 2024)
    ($11.1M)
    Enterprise value
    ($12.2M)

    Footer menu